A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?-Reference-Cited by-同舟云学术

A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?

Published:2018-07 Issue: Volume:127 Page:29-41
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Vos Shoko,van Diest Paul Joannes,Moelans Cathy Beatrice

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference99 articles.

1. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group;Alsop;J. Clin. Oncol.,2012

2. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation;Alvarez;Clin. Cancer Res.,2005

3. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies;Antoniou;Am. J. Hum. Genet.,2003

4. BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression;Bal;Virchows Arch.,2012

5. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study;Baldwin;Cancer Res.,2000

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNA‑mediated approaches in ovarian cancer therapy: A comprehensive systematic review;Oncology Letters;2024-08-12

2. Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women;International Journal of Molecular Sciences;2024-03-07

3. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status;BMC Medicine;2024-01-09

4. BRCA1 Promoter Hypermethylation in Malignant Breast Tumors and in the Histologically Normal Adjacent Tissues to the Tumors: Exploring Its Potential as a Biomarker and Its Clinical Significance in a Translational Approach;Genes;2023-08-25

5. A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620);Breast Cancer Research and Treatment;2023-02-28